Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MORNASDAQ:PTGXNASDAQ:QURENASDAQ:SRRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/APTGXProtagonist Therapeutics$53.34-1.1%$47.94$30.67▼$60.60$3.31B2.25898,091 shs2.28 million shsQUREuniQure$14.21-5.9%$14.20$3.73▼$19.18$778.42M0.081.95 million shs3.31 million shsSRRKScholar Rock$34.04-6.3%$31.65$6.76▼$46.98$3.23B0.281.29 million shs3.22 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMORMorphoSys0.00%0.00%0.00%0.00%+4.18%PTGXProtagonist Therapeutics0.00%-5.38%+16.82%+1.54%+65.34%QUREuniQure0.00%-7.37%-6.27%-3.79%+209.59%SRRKScholar Rock0.00%+4.90%+13.47%+0.68%+302.84%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMORMorphoSysN/AN/AN/AN/AN/AN/AN/AN/APTGXProtagonist Therapeutics1.3262 of 5 stars2.52.00.00.02.02.50.0QUREuniQure1.94 of 5 stars3.51.00.00.01.32.50.6SRRKScholar Rock4.3331 of 5 stars3.62.00.04.42.53.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMORMorphoSys 0.00N/AN/AN/APTGXProtagonist Therapeutics 3.00Buy$66.1023.92% UpsideQUREuniQure 2.91Moderate Buy$37.82166.14% UpsideSRRKScholar Rock 3.14Buy$42.6725.34% UpsideCurrent Analyst Ratings BreakdownLatest QURE, MOR, SRRK, and PTGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.006/17/2025PTGXProtagonist TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$72.006/3/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.006/3/2025SRRKScholar RockLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/30/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.005/29/2025QUREuniQureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.005/19/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.005/19/2025QUREuniQureCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/14/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.005/12/2025QUREuniQureGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.005/12/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMORMorphoSys$238.28M11.99N/AN/A$0.35 per share54.17PTGXProtagonist Therapeutics$434.43M7.61$4.52 per share11.81$11.33 per share4.71QUREuniQure$27.12M28.70N/AN/A($0.14) per share-101.50SRRKScholar Rock$33.19M97.38N/AN/A$3.94 per share8.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMORMorphoSys-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/APTGXProtagonist Therapeutics$275.19M$0.7571.12N/AN/A27.04%9.22%8.31%8/5/2025 (Estimated)QUREuniQure-$239.56M-$4.39N/AN/AN/A-1,077.05%-483.87%-34.28%8/7/2025 (Estimated)SRRKScholar Rock-$246.29M-$2.53N/AN/AN/AN/A-118.22%-82.01%8/6/2025 (Estimated)Latest QURE, MOR, SRRK, and PTGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025SRRKScholar Rock-$0.63-$0.67-$0.04-$0.67N/AN/A5/9/2025Q1 2025QUREuniQure-$1.07-$0.82+$0.25-$0.82$5.93 million$1.57 million5/6/2025Q1 2025PTGXProtagonist Therapeutics-$0.50-$0.19+$0.31-$0.19$30.44 million$28.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMORMorphoSysN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMORMorphoSys4.981.381.38PTGXProtagonist TherapeuticsN/A17.2517.26QUREuniQure1.5311.9911.99SRRKScholar Rock0.1610.2510.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMORMorphoSys18.38%PTGXProtagonist Therapeutics98.63%QUREuniQure78.83%SRRKScholar Rock91.08%Insider OwnershipCompanyInsider OwnershipMORMorphoSys0.05%PTGXProtagonist Therapeutics4.90%QUREuniQure4.79%SRRKScholar Rock13.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMORMorphoSys730150.62 million150.55 millionNot OptionablePTGXProtagonist Therapeutics12061.98 million58.95 millionOptionableQUREuniQure50054.78 million52.15 millionOptionableSRRKScholar Rock14094.95 million82.32 millionOptionableQURE, MOR, SRRK, and PTGX HeadlinesRecent News About These CompaniesScholar Rock (NASDAQ:SRRK) Trading Down 5.7% - Time to Sell?June 22 at 4:21 AM | americanbankingnews.comScholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Recommendation of "Buy" from BrokeragesJune 21 at 2:21 AM | americanbankingnews.comScholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Recommendation of "Buy" from AnalystsJune 21 at 2:19 AM | marketbeat.comScholar Rock (NASDAQ:SRRK) Shares Down 5.7% - Should You Sell?June 20 at 12:28 PM | marketbeat.comScholar Rock (SRRK) Jumps 16.6% After Successful Weight Loss Drug TrialJune 19, 2025 | insidermonkey.comScholar Rock data show promise for muscle-preserving combo with ZepboundJune 19, 2025 | thepharmaletter.comScholar Rock (NASDAQ:SRRK) Given Outperform Rating at WedbushJune 19, 2025 | americanbankingnews.comScholar Rock (NASDAQ:SRRK) Receives Outperform Rating from WedbushJune 18, 2025 | marketbeat.comScholar Rock says its drug preserved lean mass in patients taking ZepoundJune 18, 2025 | statnews.comScholar Rock Jumps on Weight Loss Data for Zepbound/Repurposed Antibody ComboJune 18, 2025 | biospace.comScholar Rock's SMA drug helps weight loss patients on Zepbound retain muscle in phase 2 trialJune 18, 2025 | fiercebiotech.comScholar Rock stock soars after drug shows promise in preserving lean mass during weight lossJune 18, 2025 | au.investing.comScholar Rock lead asset causes higher quality weight loss with Lilly’s obesity drugJune 18, 2025 | msn.comScholar Rock Stock Soars on Biopharma Firm's Weight-Loss Drug Trial ResultsJune 18, 2025 | msn.comScholar Rock Stock Soars After Investigational Drug Helps Preserve Lean Mass: Retail Flags Lack Of Incremental Weight LossJune 18, 2025 | msn.comWhy Scholar Rock Shares Are Soaring TodayJune 18, 2025 | fool.comScholar Rock (NASDAQ:SRRK) Shares Gap Up - What's Next?June 18, 2025 | marketbeat.comScholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss StudyJune 18, 2025 | benzinga.comScholar Rock Shares Jump on Positive Results from Weight Loss TrialJune 18, 2025 | marketwatch.comScholar Rock's drug helps preserve lean mass in mid-stage trialJune 18, 2025 | reuters.comGAMMA Investing LLC Has $962,000 Stock Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK)June 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesCoca-Cola Stock Has Momentum, PepsiCo May Be the Better BuyBy Chris Markoch | May 29, 2025View Coca-Cola Stock Has Momentum, PepsiCo May Be the Better Buy3 Stocks Set to Double—And There's Still Time to BuyBy Nathan Reiff | June 12, 2025View 3 Stocks Set to Double—And There's Still Time to BuyTesla: Why Analysts Think It Could Jump Another 47%By Sam Quirke | May 27, 2025View Tesla: Why Analysts Think It Could Jump Another 47%Trump Orders Nuclear Overhaul: These 3 Stocks Stand to BenefitBy Dan Schmidt | May 28, 2025View Trump Orders Nuclear Overhaul: These 3 Stocks Stand to Benefit2 Red-Hot Stocks With High RSIs and More Upside to ComeBy Sam Quirke | May 27, 2025View 2 Red-Hot Stocks With High RSIs and More Upside to ComeQURE, MOR, SRRK, and PTGX Company DescriptionsMorphoSys NASDAQ:MOR$18.96 0.00 (0.00%) As of 06/20/2025MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Protagonist Therapeutics NASDAQ:PTGX$53.34 -0.58 (-1.08%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$53.34 +0.00 (+0.01%) As of 06/20/2025 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.uniQure NASDAQ:QURE$14.21 -0.89 (-5.89%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$14.02 -0.20 (-1.37%) As of 06/20/2025 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.Scholar Rock NASDAQ:SRRK$34.04 -2.28 (-6.28%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$33.91 -0.13 (-0.38%) As of 06/20/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
